Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 481-488 , May 2006

In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers

  • Michael F. Giblin

      Affiliations

    • Research Service, Harry S. Truman Memorial Veterans Administration Hospital, Columbia, MO 65201, USA
    • Department of Radiology, University of Missouri-Columbia School of Medicine, Columbia, MO 65211, USA
    • Corresponding Author InformationCorresponding author. Research Service, Harry S. Truman Memorial Veterans Administration Hospital, Columbia, MO 65201, USA. Tel.: +1 573 814 6000x3669; fax: +1 573 882 6129.
    • ,
  • Gary L. Sieckman

      Affiliations

    • Research Service, Harry S. Truman Memorial Veterans Administration Hospital, Columbia, MO 65201, USA
    • ,
  • Tiffani D. Shelton

      Affiliations

    • Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia, MO 65211, USA
    • ,
  • Timothy J. Hoffman

      Affiliations

    • Research Service, Harry S. Truman Memorial Veterans Administration Hospital, Columbia, MO 65201, USA
    • Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia, MO 65211, USA
    • ,
  • Leonard R. Forte

      Affiliations

    • Research Service, Harry S. Truman Memorial Veterans Administration Hospital, Columbia, MO 65201, USA
    • Department of Medical Pharmacology and Physiology, University of Missouri-Columbia School of Medicine, Columbia, MO 65211, USA
    • ,
  • Wynn A. Volkert

      Affiliations

    • Research Service, Harry S. Truman Memorial Veterans Administration Hospital, Columbia, MO 65201, USA
    • Department of Radiology, University of Missouri-Columbia School of Medicine, Columbia, MO 65211, USA

Received 18 October 2005 ,Revised 12 January 2006 ,Accepted 25 January 2006.

References 

  1. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005;23:4553–4560
  2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476–487
  3. Ellis LM. Bevacizumab. Nat Rev Drug Discov. 2005;4:S8–S9
  4. Goldberg RM. Cetuximab. Nat Rev Drug Discov. 2005;4:S10–S11
  5. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;4:389–427
  6. Riccabona G, Decristoforo C. Peptide targeted imaging of cancer. Cancer Biother Radiopharm. 2003;18:675–687
  7. Giblin MF, Veerendra B, Smith CJ. Radiometallation of receptor-specific peptides for diagnosis and treatment of human cancer. In Vivo. 2005;19:9–30
  8. Heppeler A, Froidevaux S, Eberle AM, Maecke HR. Receptor targeting for tumor localization and therapy with radiopeptides. Curr Med Chem. 2000;7:971–994
  9. Forster GJ, Engelbach M, Brockmann J, Reber H, Buchholz HG, Macke HR, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide. Eur J Nucl Med. 2001;28:1743–1750
  10. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des. 2002;8:1781–1807
  11. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46:13S–17S
  12. Van De Wiele C, Dumont F, Van Belle S, Slegers G, Peers SH, Dierckx RA. Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumor imaging?. Nucl Med Comm. 2001;22:5–15
  13. Smith CJ, Volkert WA, Hoffman TJ. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol. 2003;30:861–868
  14. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 2004;64:6707–6715
  15. Giblin MF, Wang N, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A. 1998;95:12814–12818
  16. Froidevaux S, Calame-Christe M, Tanner H, Sumanovski L, Eberle AN. A novel DOTA-α-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med. 2002;43:1699–1706
  17. Cheng Z, Chen J, Miao Y, Owen NK, Quinn TP, Jurisson SS. Modification of the structure of a metallopeptide: synthesis and biological evaluation of 111In-labeled DOTA-conjugated rhenium-cyclized α-MSH analogues. J Med Chem. 2002;45:3048–3056
  18. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994;33:1116–1121
  19. Thakur ML, Aruva MR, Gariepy J, Acton P, Rattan S, Prasad S, et al. PET imaging of oncogene overexpression using 64Cu vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. J Nucl Med. 2004;45:1381–1389
  20. Volkert WA, Hoffman TJ. Therapeutic radiopharmaceuticals. Chem Rev. 1999;99:2269–2292
  21. Riccabona G, Decristoforo C. Peptide targeted imaging of cancer. Cancer Biother Radiopharm. 2003;18:675–687
  22. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902–1909
  23. de Jong M, Bakker WH, Krenning EP, Breeman WAP, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding, and biodistribution of [DOTA0, D-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997;24:368–371
  24. Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-Dphe1,Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumors. Eur J Nucl Med. 1998;25:668–674
  25. Lewis JS, Wang M, Laforest R, Wang F, Erion JL, Bugaj JE, et al. Toxicity and dosimetry of 177Lu-DOTA-Y3-octreotate in a rat model. Int J Cancer. 2001;94:873–877
  26. Breeman WAP, Mearadji A, Capello A, Bernard BF, van Eijck CHJ, Krenning EP, et al. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model. Int J Cancer. 2003;104:376–379
  27. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumors with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417–422
  28. Guarino A, Cohen M, Thompson M, Dharmsathaphorn K, Giannella R. T84 cell receptor binding and guanyl cyclase activation by Escherichia coli heat-stable toxin. Am J Physiol. 1987;253:G775–G780
  29. Schulz S, Green CK, Yuen PS, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell. 1990;63:941–948
  30. Carrithers SL, Parkinson SJ, Goldstein S, Park P, Robertson DC, Waldman SA. Escherichia coli heat-stable toxin receptors in human colonic tumors. Gastroenterology. 1994;107:1653–1661
  31. Gali H, Sieckman GL, Hoffman TJ, Owen NK, Chin DT, Forte LR, et al. In vivo evaluation of an 111In-labeled ST-peptide analog for specific targeting of human colon cancers. Nucl Med Biol. 2001;28:903–909
  32. Gali H, Sieckman GL, Hoffman TJ, Owen NK, Mazuru DG, Forte LR, et al. Chemical synthesis of Escherichia coli STh analogs by regioselective disulfide bond formation: biological evaluation of an 111In-DOTA-Phe19-STh analog for specific targeting of human colon cancers. Bioconjug Chem. 2002;13:224–231
  33. Wolfe HR, Mendizabal M, Lleong E, Cuthbertson A, Desai V, Pullan S, et al. In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C-specific ligand. J Nucl Med. 2002;43:392–399
  34. Giblin MF, Gali H, Sieckman GL, Owen NK, Hoffman TJ, Forte LR, et al. In vitro and in vivo comparison of human Escherichia coli heat-stable peptide analogs incorporating the 111In-DOTA group and distinct linker moieties. Bioconjug Chem. 2004;15:872–880
  35. Shimonishi Y, Hidaka Y, Koizumi M, Hane M, Aimoto S, Takeda T, et al. Mode of disulfide bond formation of a heat-stable enterotoxin (STh) produced by a human strain of enterotoxigenic Escherichia coli. FEBS Lett. 1987;215:165–170
  36. Gariepy J, Judd AK, Schoolnik GK. Importance of disulfide bridges in the structure and activity of Escherichia coli enterotoxin ST1b. Proc Natl Acad Sci U S A. 1987;84:8907–8911
  37. Onthank DC, Liu S, Silva PJ, Barrett JA, Harris TD, Robinson SP, et al. 90Y and 111In complexes of a DOTA-conjugated integrin αVβ3 receptor antagonist: different but biologically equivalent. Bioconjug Chem. 2004;15:235–241
  38. Liu S, Pietryka J, Ellars CE, Edwards DS. Comparison of yttrium and indium complexes of DOTA-BA and DOTA-MBA: models for 90Y- and 111In-labeled DOTA-biomolecule conjugates. Bioconjug Chem. 2002;13:902–913
  39. Carrasquillo LA, White JD, Paik CH, Raubitschek A, Le N, Rotman M, et al. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA anti-Tac monoclonal antibody distribution. J Nucl Med. 1999;40:268–276
  40. Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, et al. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?. J Nucl Med. 2005;46:634–641
  41. Miao Y, Hoffman TJ, Quinn TP. Tumor-targeting properties of 90Y- and 177Lu-labeled a-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol. 2005;32:485–493
  42. Smith CJ, Gali H, Sieckman GL, Hayes DL, Owen NK, Mazuru DG, et al. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7–14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol. 2003;30:101–109
  43. Eisenwiener K, Prata MIM, Buschmann I, Zhang H, Santos AC, Wenger S, et al. NODATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem. 2002;13:530–541
  44. Shen S, DeNardo SJ, Richman CM, Yuan A, Siantar CH, O'Donnell RT, et al. Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry. J Nucl Med. 2005;46:1034–1041
  45. Spies SM. Imaging and dosing in radioimmunotherapy with yttrium-90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med. 2004;34:10–13

PII: S0969-8051(06)00015-1

doi: 10.1016/j.nucmedbio.2006.01.009

Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 481-488 , May 2006

Article Tools

* Image Usage & Resolution